McKesson (MCK) PT Raised to $715 at Jefferies

Jefferies analyst Rob Dickerson raised the price target on McKesson (NYSE: MCK) to $715.00 (from $607.00) while maintaining a Buy rating.

The analyst comments "We hosted MCK's CFO Britt Vitalone at our 2024 London H/C Conference. Key takes: (1) Oncology & Biopharma Svcs are some of MCK's key growth/strategic pillars, (2) the accretion from the pending FCS deal appear impressive, while Cell & Gene therapies bring a potential growth driver, and (3) despite some NT noise, the LT outlook across its business lines remains strong (maintained LT earnings growth guidance ranges in US Rx, Medical, and RxTS). PT raised to $715."

You May Also Be Interested In

• Rockstar Energy founder seeks CEO role at Celsius Holdings
• Freedom Broker Upgrades Xpel inc. (XPEL) to Buy
• SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59